BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

169 related articles for article (PubMed ID: 28767180)

  • 1. Improved union and bone strength in a mouse model of NF1 pseudarthrosis treated with recombinant human bone morphogenetic protein-2 and zoledronic acid.
    Deo N; Cheng TL; Mikulec K; Peacock L; Little DG; Schindeler A
    J Orthop Res; 2018 Mar; 36(3):930-936. PubMed ID: 28767180
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A Combination of rhBMP-2 (Recombinant Human Bone Morphogenetic Protein-2) and MEK (MAP Kinase/ERK Kinase) Inhibitor PD0325901 Increases Bone Formation in a Murine Model of Neurofibromatosis Type I Pseudarthrosis.
    El-Hoss J; Cheng T; Carpenter EC; Sullivan K; Deo N; Mikulec K; Little DG; Schindeler A
    J Bone Joint Surg Am; 2014 Jul; 96(14):e117. PubMed ID: 25031379
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Distal tibial fracture repair in a neurofibromatosis type 1-deficient mouse treated with recombinant bone morphogenetic protein and a bisphosphonate.
    Schindeler A; Birke O; Yu NY; Morse A; Ruys A; Baldock PA; Little DG
    J Bone Joint Surg Br; 2011 Aug; 93(8):1134-9. PubMed ID: 21768643
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A murine model of neurofibromatosis type 1 tibial pseudarthrosis featuring proliferative fibrous tissue and osteoclast-like cells.
    El-Hoss J; Sullivan K; Cheng T; Yu NY; Bobyn JD; Peacock L; Mikulec K; Baldock P; Alexander IE; Schindeler A; Little DG
    J Bone Miner Res; 2012 Jan; 27(1):68-78. PubMed ID: 21956219
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Maximizing bone formation in posterior spine fusion using rhBMP-2 and zoledronic acid in wild type and NF1 deficient mice.
    Bobyn J; Rasch A; Kathy M; Little DG; Schindeler A
    J Orthop Res; 2014 Aug; 32(8):1090-4. PubMed ID: 24719295
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Manipulation of the anabolic and catabolic responses with BMP-2 and zoledronic acid in a rat femoral fracture model.
    Doi Y; Miyazaki M; Yoshiiwa T; Hara K; Kataoka M; Tsumura H
    Bone; 2011 Oct; 49(4):777-82. PubMed ID: 21777711
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Guided tissue engineering for healing of cancellous and cortical bone using a combination of biomaterial based scaffolding and local bone active molecule delivery.
    Raina DB; Qayoom I; Larsson D; Zheng MH; Kumar A; Isaksson H; Lidgren L; Tägil M
    Biomaterials; 2019 Jan; 188():38-49. PubMed ID: 30321863
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Modeling bone morphogenetic protein and bisphosphonate combination therapy in wild-type and Nf1 haploinsufficient mice.
    Schindeler A; Ramachandran M; Godfrey C; Morse A; McDonald M; Mikulec K; Little DG
    J Orthop Res; 2008 Jan; 26(1):65-74. PubMed ID: 17787010
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Combination therapy with low-dose teriparatide and zoledronate contributes to fracture healing on rat femoral fracture model.
    Tsubouchi Y; Ikeda S; Kataoka M; Tsumura H
    J Orthop Surg Res; 2018 Oct; 13(1):267. PubMed ID: 30359257
    [TBL] [Abstract][Full Text] [Related]  

  • 10. rhBMP-2 and Intramedullary Fixation in Congenital Pseudarthrosis of the Tibia.
    Richards BS; Anderson TD
    J Pediatr Orthop; 2018 Apr; 38(4):230-238. PubMed ID: 27261960
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effect of recombinant human bone morphogenetic protein-2 on fracture healing in a goat tibial fracture model.
    Welch RD; Jones AL; Bucholz RW; Reinert CM; Tjia JS; Pierce WA; Wozney JM; Li XJ
    J Bone Miner Res; 1998 Sep; 13(9):1483-90. PubMed ID: 9738522
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Systemic Administration of Sclerostin Antibody Enhances Bone Morphogenetic Protein-Induced Femoral Defect Repair in a Rat Model.
    Tinsley BA; Dukas A; Pensak MJ; Adams DJ; Tang AH; Ominsky MS; Ke HZ; Lieberman JR
    J Bone Joint Surg Am; 2015 Nov; 97(22):1852-9. PubMed ID: 26582615
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A novel low-molecular-weight compound enhances ectopic bone formation and fracture repair.
    Wong E; Sangadala S; Boden SD; Yoshioka K; Hutton WC; Oliver C; Titus L
    J Bone Joint Surg Am; 2013 Mar; 95(5):454-61. PubMed ID: 23467869
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Manipulation of the anabolic and catabolic responses with OP-1 and zoledronic acid in a rat critical defect model.
    Little DG; McDonald M; Bransford R; Godfrey CB; Amanat N
    J Bone Miner Res; 2005 Nov; 20(11):2044-52. PubMed ID: 16234978
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Early inhibitory effects of zoledronic acid in tooth extraction sockets in dogs are negated by recombinant human bone morphogenetic protein.
    Gerard DA; Carlson ER; Gotcher JE; Pickett DO
    J Oral Maxillofac Surg; 2014 Jan; 72(1):61-6. PubMed ID: 23891015
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The inhibitory effect of zoledronate on early-stage osteoinduction by recombinant human bone morphogenetic protein 2 in an osteoporosis model.
    Lee JH; Baek HR; Lee KM; Zheng GB; Shin SJ; Jin YZ
    Growth Factors; 2015; 33(3):220-8. PubMed ID: 26099999
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effects of combined teriparatide and zoledronic acid on posterior lumbar vertebral fusion in an aged ovariectomized rat model of osteopenia.
    Yishake M; Yasen M; Jiang L; Liu W; Xing R; Chen Q; Lin H; Dong J
    J Orthop Res; 2018 Mar; 36(3):937-944. PubMed ID: 28796280
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Manipulation of anabolic and catabolic responses with bone morphogenetic protein and zoledronic acid in a rat spinal fusion model.
    Kodera R; Miyazaki M; Yoshiiwa T; Kawano M; Kaku N; Tsumura H
    Bone; 2014 Jan; 58():26-32. PubMed ID: 24103577
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The effects of combined human parathyroid hormone (1-34) and zoledronic acid treatment on fracture healing in osteoporotic rats.
    Li YF; Zhou CC; Li JH; Luo E; Zhu SS; Feng G; Hu J
    Osteoporos Int; 2012 Apr; 23(4):1463-74. PubMed ID: 21892678
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Gelatin- hydroxyapatite- calcium sulphate based biomaterial for long term sustained delivery of bone morphogenic protein-2 and zoledronic acid for increased bone formation: In-vitro and in-vivo carrier properties.
    Raina DB; Larsson D; Mrkonjic F; Isaksson H; Kumar A; Lidgren L; Tägil M
    J Control Release; 2018 Feb; 272():83-96. PubMed ID: 29329716
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.